How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants? medrxivpreprint CWRUSOM COVID19 coronavirus covid Paxlovid
By Shanet Susan AlexAug 9 2022Reviewed by Danielle Ellis, B.Sc. In a recent article posted to the medRxiv* preprint server, scientists analyzed the differences between severe acute respiratory syndrome coronavirus 2 rebound associated with the Omicron BA.2.12.1 and BA.5 sublineages post-Paxlovid therapy in the United States .
About the study The present retrospective cohort research aimed to compare the risks of COVID-19 rebound in individuals who had SARS-CoV-2 infections during the BA.2.12.1 and BA.5 subvariant predominance phases in the US after receiving Paxlovid treatments. The authors compared the chances for SARS-CoV-2 rebound outcomes in the BA.2.12.1 and BA.5 groups pre- and post-propensity-score matching for factors including age, gender, and ethnicity relevant to SARS-CoV-2 infections and outcomes. They monitored rebound COVID-19 and symptoms from two to eight days post-Paxlovid treatment, and Kaplan-Meier survival analysis was used to calculate the likelihood of outcomes.
In the BA.2.12.1 cohort and the BA.5 cohort, the cumulative probability of SARS-CoV-2 rebound infection two to eight days following Paxlovid therapy was 3.42% and 2.81%, respectively. The BA.5 group had a higher immediate threat of rebound symptoms versus the BA.2.12.1 group, but there was no difference in the likelihood of rebound infections. Following propensity-score matching, the BA.5 cohort had higher immediate odds of rebound infections and symptoms versus the matched BA.2.12.1 group.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariantsStudy suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariants biorxivpreprint HokkaidoUnivPR Omicron coronavirus covid COVID19 SARSCoV2 inflammation evolution
Read more »
Study finds COVID associated with abnormal placental pathologies in nearly 50% of cohortStudy finds COVID associated with abnormal placental pathologies in nearly 50% of cohort ChildHealth Coronavirus Disease COVID Placenta Pregnancy WomensHealth IFPA_Official
Read more »
The safety and preliminary efficacy of OP-101 in patients with severe COVID-19The safety and preliminary efficacy of OP-101 in patients with severe COVID-19 ScienceTM ScienceMagazine UTAustin HopkinsMedicine AveraHealth BrowardHealth COVID19 coronavirus covid virus nanotherapy
Read more »
Study suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariantsStudy suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariants biorxivpreprint HokkaidoUnivPR Omicron coronavirus covid COVID19 SARSCoV2 inflammation evolution
Read more »
Biden Leaves White House for First Time Since Getting COVIDEnding his most recent COVID-19 isolation, President Joe Biden on Sunday left the White House for the first time since becoming infected with COVID-19
Read more »
China's Hainan Beach Resort Expands COVID-19 LockdownsThe capital of China's Hainan province has locked down its residents for 13 hours
Read more »